IMEIK
IMEIK
IMEIK is a leading Chinese biomedical soft tissue repair materials manufacturer.
IMEIK, founded in 2004, has been developed based on the research, development, and transformation of biomedical soft tissue repair materials. The founder is Jian Jun. Listed on the Shanghai Stock Exchange in September 2020, the company's major shareholders are Jian Jun, Ningbo Zhixingjun Investment Management Limited Partnership, and GANNETT PEAK LIMITED. Rivals with the direct and indirect competition with IMEIK include Haohai Biological, Bloomage BioTech.
- All
- News
- Analysis
- Research
Briefing Updated 3 hours ago
· Healthcare
Focusing on the digital transformation of bone and joint disease treatment, Aiqiao medical completed tens of millions of yuan of PREA round financing
Briefing Dec 09, 2021 10:39 AM
Baijiu plate strength, mouth cellar line exceeds 10%
In depth
Briefing Oct 22, 2021 10:13 PM
· Real Estate
AMEC: the capital increase and acquisition of part of the equity of hoons biopharma in South Korea have been completed
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Oct 19, 2021 06:56 AM
· Financials
The investment banking business was strictly supervised, and seven securities companies received fines
Briefing Oct 17, 2021 06:26 PM
· Healthcare
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
Briefing Sep 24, 2021 11:28 AM
· Healthcare
The medical and American plate rose sharply
Briefing Aug 23, 2021 07:46 PM
· Healthcare
AMEC: the net profit in the first half of the year was 425 million yuan, a year-on-year increase of 188.86%
In depth
Healthcare
Zhaoke Ophthalmology Partners with Yidu Tech's HLT on Ophthalmic Clinical Research
On 16 December, Zhaoke Ophthalmology (SEHK: 6622) and HappyLife Technology ("HLT"), an affiliate of Yidu Tech Inc. ("Yidu Tech", SEHK: 2158), announced to have signed a Letter of Intent with an objective to accelerate the development of innovative clinical research programs for the Chinese ophthalmic market.
Dec 16, 2021 02:04 PM
Briefing Jul 08, 2021 07:41 PM
· Financials
Aimike's reply to the letter of concern: after obtaining the equity of huons bio, it will not have a significant adverse impact on the company's production and operation
In depth
Ministry of Commerce: making a negative list of cross border service trade of Hainan free trade port
See more
Related Companies
EqualOcean Analysis
- A Late Starter, ByteDance Begins to Accelerate Its Effort in Healthcare
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Digital Health on a Rise: JD Health Stocks Spike 70% on First Trading Day
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.